ELIQUIS® (apixaban) Returned to Preferred Formulary Status
Effective July 1, 2022, ELIQUIS® (apixaban) returned to preferred formulary status (Tier 2) for CareFirst Commercial Formularies. This formulary addition ensures access to cost-effective therapy for our members and allows ELIQUIS® (apixaban) to be available for your patients without the need to request a formulary exception. Full prescribing information can be found here: